This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Konadu, E. Y.
Right arrow Articles by Szu, S. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Konadu, E. Y.
Right arrow Articles by Szu, S. C.

 Previous Article  |  Next Article 

Infection and Immunity, March 2000, p. 1529-1534, Vol. 68, No. 3
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Phase 1 and Phase 2 Studies of Salmonella enterica Serovar Paratyphi A O-Specific Polysaccharide-Tetanus Toxoid Conjugates in Adults, Teenagers, and 2- to 4-Year-Old Children in Vietnam

Edward Y. Konadu,1 Feng-Ying C. Lin,1 Vô Anh Hó,2 Nguyen Thi Thanh Thuy,3 Phan Van Bay,2 Tran Cong Thanh,3 Ha Ba Khiem,3 Dang Duc Trach,4 Arthur B. Karpas,1 Jianping Li,1 Dolores A. Bryla,1 John B. Robbins,1 and Shousun C. Szu1,*

National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892-2720,1 and Huu Nghi Hospital, Cao Lânh District, Dong Thap Province,2 Pasteur Institut, Ho Chi Minh City,3 and National Institute of Hygiene and Epidemiology, Hanoi,4 Vietnam

Received 23 July 1999/Returned for modification 27 October 1999/Accepted 26 November 1999

Salmonella enterica serovar Paratyphi A O-specific polysaccharide (O-SP) was activated with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) and bound to tetanus toxoid (TT) with adipic acid dihydrazide as a linker (SPA-TT1) or directly (SPA-TT2). In mice, these two conjugates elicited high levels of immunoglobulin G (IgG) anti-lipopolysaccharide (LPS) in serum with bactericidal activity (E. Konadu, J. Shiloach, D. A. Bryla, J. B. Robbins, and S. C. Szu, Infect. Immun. 64:2709-2715, 1996). The safety and immunogenicity of the two conjugates were then evaluated sequentially in Vietnamese adults, teenagers, and 2- to 4-year-old children. None of the vaccinees experienced significant side effects, and all had preexisting LPS antibodies. At 4 weeks after injection, there were significant increases of the geometric mean IgG and IgM anti-LPS levels in the adults and teenagers: both conjugates elicited a greater than fourfold rise in the IgG anti-LPS level in serum in >= 80% of the volunteers. SPA-TT2 elicited slightly higher, though not statistically significantly, levels of IgG anti-LPS than did SPA-TT1 in these age groups. Accordingly, only SPA-TT2 was evaluated in the 2- to 4-year-old children. On a random basis, one or two injections were administered 6 weeks apart to the children. No significant side effects were observed, and the levels of preexisting anti-LPS in serum were similar in children of all ages. A significant rise in the IgG anti-LPS titer was elicited by the first injection (P = 0.0001); a second injection did not elicit a booster response. Representative sera from all groups had bactericidal activity that could be adsorbed by S. enterica serovar Paratyphi A LPS.


* Corresponding author. Mailing address: National Institute of Child Health and Human Development, National Institutes of Health, Bldg. 6, Room 424, Bethesda, MD 20892. Phone: (301) 496-4524. Fax: (301) 402-9108. E-mail: scszu{at}helix.nih.gov.


Infection and Immunity, March 2000, p. 1529-1534, Vol. 68, No. 3
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.